Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pai.14215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting the Common Pathway: IL-4/IL-13 Blockade Across the Spectrum of Primary Atopic Disorders.
J Allergy Clin Immunol
September 2025
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA. Electronic address:
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.
Dermatol Ther (Heidelb)
September 2025
Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada.
Introduction: Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and effective in improving itch and lesion clearance in patients ≥ 12 years old.
View Article and Find Full Text PDFReduced Risk of Neurodevelopmental and Psychiatric Disorders With Dupilumab Use in Pediatric Atopic Dermatitis.
Dermatitis
September 2025
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis.
Pediatr Dermatol
September 2025
Department of Dermatology, Medical College of Wisconsin, Milwaukee, USA.
Dupilumab is an IL-4Rα and IL-13 inhibitor FDA-approved for the treatment of atopic dermatitis (AD) in patients 6 months and older. Guidelines recommend against live-attenuated vaccines due to limited safety data. We conducted a retrospective chart review of 233 patients aged 6 months to 10 years receiving dupilumab for AD at Children's Wisconsin, which showed that 19 received live vaccines during the study period.
View Article and Find Full Text PDFDupilumab-Induced Graves' Disease in an Adult With Chronic Rhinosinusitis and Nasal Polyposis.
Cureus
July 2025
Endocrinology, Diabetes, and Metabolism, Unidade Local de Saúde de Lisboa Ocidental, Hospital de Egas Moniz, Lisbon, PRT.
Dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and IL-13, is widely used for the treatment of type 2 inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Although generally well-tolerated, dupilumab has been linked to rare thyroid-related events. We report a case of Graves' disease (GD) in a 47-year-old man with severe nasal polyposis who developed heat intolerance and weight loss within six to eight weeks of starting dupilumab.
View Article and Find Full Text PDF